Price T Rowe Associates Inc Corvus Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 26,299 shares of CRVS stock, worth $192,508. This represents 0.0% of its overall portfolio holdings.
Number of Shares
26,299Holding current value
$192,508% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRVS
# of Institutions
101Shares Held
38.9MCall Options Held
98.5KPut Options Held
226K-
Orbimed Advisors LLC San Diego, CA7.17MShares$52.4 Million1.02% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.04MShares$51.6 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.28MShares$24 Million0.0% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$24 Million9.69% of portfolio
-
Rtw Investments, LP New York, NY2.68MShares$19.6 Million0.16% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $341M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...